Radiotherapy and hormonal treatment

摘要

Combined modality therapy has developed as the standard of care for the majority of cancers using combinations of chemoradiation as either non-surgical radical options as, for example, in cancers from head and neck, lung, cervix and oesophagus or in combination with surgery, as in breast cancer. In prostate cancer, hormonal therapy is the appropriate and most effective systemic treatment option. Phase III randomised trials have unequivocally demonstrated the benefits of both neoadjuvant androgen suppression with external beam radiotherapy in patients with intermediate and high risk localised disease [1] and for adjuvant therapy in men presenting with advanced stage, high grade (Gleason sum >=8) disease [2-9].